ASX · GTG.AX
Genetic Technologies Limited
A$0.04A$0.00 (0.0%)
Genetic Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 78.92% below the high.
Loading market information…
ASX · PKY.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 01:39 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Pathkey.AI Ltd’s quoted price sits in the lower half of its reported 52-week range, 78.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pathkey.AI Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.04A$0.00 (0.0%)
Genetic Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 78.92% below the high.
A$0.02A$0.00 (0.0%)
Cann Global Limited’s quoted price sits in the lower half of its reported 52-week range, 27.59% below the high.
A$0.02A$0.00 (0.0%)
Oventus Medical Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
A$0.00A$0.00 (0.0%)
Analytica Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
A$0.00-A$0.00 (-50.0%)
Medibio Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
A$0.02A$0.00 (0.0%)
Bod Science Limited’s quoted price sits in the lower half of its reported 52-week range, 11.11% below the high.
A$0.01A$0.00 (0.0%)
Universal Biosensors, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.25% below the high.
A$0.07A$0.00 (0.0%)
Visioneering Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.6% below the high.
